To test if a CDK2 inhibitor in combination with etoposide is anti-tumorigenic in vivo, we used the OVCAR-3 xenograft, a model previously used to validate CDK2 as an oncogenic driver in CCNE1-amplified ovarian cancer (54). This evidence concerns the gene CDK2 and ovarian carcinoma.